Abstract
References
- Vigneswaran K, Neill S, Hadjipanayis CG. Beyond the World Health Organization grading of infiltrating gliomas: advances in the molecular genetics of glioma classification. Ann Transl Med. 2015;3(7):95. doi: 10.3978/j.issn.2305-5839.2015.03.57
- McNamara C, Mankad K, Thust S, et al. 2021 WHO classification of tumours of the central nervous system: a review for the neuroradiologist. Neuroradiology. 2022;64(10):1919–1950.
- Chen R, Smith-Cohn M, Cohen AL, Colman H. Glioma subclassifications and their clinical significance. Neurotherapeutics. 2017;14(2):284–297.
- Haque W, Teh C, Butler EB, Teh BS. Prognostic and predictive impact of MGMT promoter methylation status in high risk grade II glioma. J Neurooncol. 2022;157(1):137–146.
- Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol. 2010;28(11):1963–1972.
- Watanabe M, Tanaka R, Takeda N. Magnetic resonance imaging and histopathology of cerebral gliomas. Neuroradiology. 1992;34:463–469.
- Schaefer PW, Grant PE, Gonzalez RG. Diffusion-weighted MR imaging of the brain. Radiology. 2000;217(2):331–345.
- Yamasaki F, Sugiyama K, Ohtaki M, et al. Glioblastom treated with postoperative radio-chemotherapy: prognostic value of apparent diffusion coefficient at MR imaging. Eur J Radiol. 2010;73(3):532–537.
- Qu J, Qin L, Cheng S, et al. Residual low ADC and high FA at the resection margin correlate with poor chemoradiation response and overall Survival in high-grade glioma patients. Eur J Radiol. 2016;85(3):657–664.
- Murakami R, Sugahara T, Nakamura H, et al. Malignant supratentorial astrocytoma treated with postoperative radiation therapy: prognostic value of pretreatment quantitative diffusion-weighted MR imaging. Radiology. 2007;243(2):493–499.
- Hein PA, Eskey CJ, Dunn JF, Hug EB. Diffusion-weighted imaging in the follow-up of treated high-grade gliomas: tumor recurrence versus radiation injury. Am J Neuroradiol. 2004;25(2):201–209.
- Calabrese E, Villanueva-Meyer JE, Rudie JD, et al. The University of California San Francisco Preoperative Diffuse Glioma MRI Dataset. Radiol Artif Intell. 2022;4(6):e220058.
- Clark K, Vendt B, Smith K, et al. The Cancer Imaging Archive (TCIA): Maintaining and operating a public information repository. J Digit Imaging. 2013;26(6):1045–1057.
- Weller M, Stupp R, Reifenberger G, et al. MGMT promoter methylation in malignant gliomas: ready for personalized medicine? Nat Rev Neurol. 2010;6(1):39–51.
- Gupta A, Omuro AM, Shah AD, et al. Continuing the search for MR imaging biomarkers for MGMT promoter methylation status: conventional and perfusion MRI revisited. Neuroradiology. 2012;54:641–643.
- Darbar A, Waqas M, Enam SF, Mahmood SD. Use of preoperative apparent diffusion coefficients to predict brain tumor grade. Cureus. 2018;10(3).
- Gates EDH, Lin JS, Weinberg JS, et al. Guiding the first biopsy in glioma patients using estimated Ki-67 maps derived from MRI: conventional versus advanced imaging. Neuro-Oncol. 2019;21(4):527–536.
- Wang Q, Zhang J, Xu X, Chen X, Xu B. Diagnostic performance of apparent diffusion coefficient parameters for glioma grading. J Neurooncol. 2018;139(1):61–6.
- Artzi M, Bokstein F, Blumenthal DT, et al. Differentiation between vasogenic-edema versus tumor-infiltrative area in patients with glioblastom during bevacizumab therapy: a longitudinal MRI study. Eur J Radiol. 2014;83(7):1250–1256.
- Ladenhauf VK, Galijasevic M, Kerschbaumer J, et al. Peritumoral ADC values correlate with the MGMT methylation status in patients with glioblastom. Cancers. 2023;15(5):1384.
- Xie Z, Li J, Zhang Y, et al. The diagnostic value of ADC histogram and direct ADC measurements for coexisting isocitrate dehydrogenase mutation and O6-methylguanine-DNA methyltransferase promoter methylation in glioma. Front Neurosci [Internet]. 2023 [cited 2023 Apr 2];16. Available from: https://www.frontiersin.org/articles/10.3389/fnins.2022.1099019
- Choi YS, Ahn SS, Kim DW, et al. Incremental prognostic value of ADC histogram analysis over MGMT promoter methylation status in patients with glioblastom. Radiology. 2016;281(1):175–184.
- Demirel E, Özer Gökaslan Ç, Dilek O, Ozdemir C, Boyaci M, Korkmaz S. Differential diagnosis of glioblastom and solitary brain metastasis – the success of artificial intelligence models created with radiomics data obtained by automatic segmentation from conventional MRI sequences. Čes Slov Neurol Neurochir. 2022;84:541.
Abstract
Aims: This study aimed to investigate the relationship between volumetric mean ADC values and MGMT promoter hypermethylation status in glioblastoma (GB) patients segmented into perilesional edema area, solid tumor area, and necrosis area.
Methods: The 212 GB patients in the University of California San Francisco Preoperative Diffuse Glioma MRI (UCSF-PDGM) dataset were retrieved from the Cancer Imaging Archive (TCIA). The mean volumetric ADC value was calculated in patients with shared segmentation data in the UCSF-PDGM dataset. The difference in mean volumetric ADC value was investigated in patients divided into groups based on MGMT promoter hypermethylation (MGMT+/ MGMT-).
Results: Of the patients in our study, 125 (59.0%) were male. The median age of the patients was 62 years (26-94). MGMT promoter hypermethylation was observed in 152 (71.7%) patients. Mean Survival was calculated as 574.14±345.57 days in the MGMT+ group and 484.68±301.71 days in MGMT- group. According to volumetric mean ADC values, a difference was observed in the solid tumor and perilesional edema areas according to MGMT promoter hypermethylation (p<0.001). In the ROC analysis, the AUC value was calculated as 0.897 for the edema area and 0.812 for the solid tumor area. MGMT+ group could be identified with a cut-off value of >1.14 in ADC measurements from the edema area with 72% sensitivity and 90% specificity. MGMT+ group could be determined with a sensitivity of 88% and specificity of 69% with a cut-off value of >1.01 in ADC measurements from the solid tumor area.
Conclusion: Volumetric ADC measurements from the perilesional edema and solid tumor areas revealed higher ADC values in the MGMT+ group.
Keywords
Glioblastoma diffusion magnetic resonance imaging MGMT hypermethylation apparent diffusion coefficient (ADC)
References
- Vigneswaran K, Neill S, Hadjipanayis CG. Beyond the World Health Organization grading of infiltrating gliomas: advances in the molecular genetics of glioma classification. Ann Transl Med. 2015;3(7):95. doi: 10.3978/j.issn.2305-5839.2015.03.57
- McNamara C, Mankad K, Thust S, et al. 2021 WHO classification of tumours of the central nervous system: a review for the neuroradiologist. Neuroradiology. 2022;64(10):1919–1950.
- Chen R, Smith-Cohn M, Cohen AL, Colman H. Glioma subclassifications and their clinical significance. Neurotherapeutics. 2017;14(2):284–297.
- Haque W, Teh C, Butler EB, Teh BS. Prognostic and predictive impact of MGMT promoter methylation status in high risk grade II glioma. J Neurooncol. 2022;157(1):137–146.
- Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol. 2010;28(11):1963–1972.
- Watanabe M, Tanaka R, Takeda N. Magnetic resonance imaging and histopathology of cerebral gliomas. Neuroradiology. 1992;34:463–469.
- Schaefer PW, Grant PE, Gonzalez RG. Diffusion-weighted MR imaging of the brain. Radiology. 2000;217(2):331–345.
- Yamasaki F, Sugiyama K, Ohtaki M, et al. Glioblastom treated with postoperative radio-chemotherapy: prognostic value of apparent diffusion coefficient at MR imaging. Eur J Radiol. 2010;73(3):532–537.
- Qu J, Qin L, Cheng S, et al. Residual low ADC and high FA at the resection margin correlate with poor chemoradiation response and overall Survival in high-grade glioma patients. Eur J Radiol. 2016;85(3):657–664.
- Murakami R, Sugahara T, Nakamura H, et al. Malignant supratentorial astrocytoma treated with postoperative radiation therapy: prognostic value of pretreatment quantitative diffusion-weighted MR imaging. Radiology. 2007;243(2):493–499.
- Hein PA, Eskey CJ, Dunn JF, Hug EB. Diffusion-weighted imaging in the follow-up of treated high-grade gliomas: tumor recurrence versus radiation injury. Am J Neuroradiol. 2004;25(2):201–209.
- Calabrese E, Villanueva-Meyer JE, Rudie JD, et al. The University of California San Francisco Preoperative Diffuse Glioma MRI Dataset. Radiol Artif Intell. 2022;4(6):e220058.
- Clark K, Vendt B, Smith K, et al. The Cancer Imaging Archive (TCIA): Maintaining and operating a public information repository. J Digit Imaging. 2013;26(6):1045–1057.
- Weller M, Stupp R, Reifenberger G, et al. MGMT promoter methylation in malignant gliomas: ready for personalized medicine? Nat Rev Neurol. 2010;6(1):39–51.
- Gupta A, Omuro AM, Shah AD, et al. Continuing the search for MR imaging biomarkers for MGMT promoter methylation status: conventional and perfusion MRI revisited. Neuroradiology. 2012;54:641–643.
- Darbar A, Waqas M, Enam SF, Mahmood SD. Use of preoperative apparent diffusion coefficients to predict brain tumor grade. Cureus. 2018;10(3).
- Gates EDH, Lin JS, Weinberg JS, et al. Guiding the first biopsy in glioma patients using estimated Ki-67 maps derived from MRI: conventional versus advanced imaging. Neuro-Oncol. 2019;21(4):527–536.
- Wang Q, Zhang J, Xu X, Chen X, Xu B. Diagnostic performance of apparent diffusion coefficient parameters for glioma grading. J Neurooncol. 2018;139(1):61–6.
- Artzi M, Bokstein F, Blumenthal DT, et al. Differentiation between vasogenic-edema versus tumor-infiltrative area in patients with glioblastom during bevacizumab therapy: a longitudinal MRI study. Eur J Radiol. 2014;83(7):1250–1256.
- Ladenhauf VK, Galijasevic M, Kerschbaumer J, et al. Peritumoral ADC values correlate with the MGMT methylation status in patients with glioblastom. Cancers. 2023;15(5):1384.
- Xie Z, Li J, Zhang Y, et al. The diagnostic value of ADC histogram and direct ADC measurements for coexisting isocitrate dehydrogenase mutation and O6-methylguanine-DNA methyltransferase promoter methylation in glioma. Front Neurosci [Internet]. 2023 [cited 2023 Apr 2];16. Available from: https://www.frontiersin.org/articles/10.3389/fnins.2022.1099019
- Choi YS, Ahn SS, Kim DW, et al. Incremental prognostic value of ADC histogram analysis over MGMT promoter methylation status in patients with glioblastom. Radiology. 2016;281(1):175–184.
- Demirel E, Özer Gökaslan Ç, Dilek O, Ozdemir C, Boyaci M, Korkmaz S. Differential diagnosis of glioblastom and solitary brain metastasis – the success of artificial intelligence models created with radiomics data obtained by automatic segmentation from conventional MRI sequences. Čes Slov Neurol Neurochir. 2022;84:541.
Details
| Primary Language | English |
|---|---|
| Subjects | Brain and Nerve Surgery (Neurosurgery) |
| Journal Section | Original Article |
| Authors | |
| Early Pub Date | July 28, 2023 |
| Publication Date | July 30, 2023 |
| Published in Issue | Year 2023 Volume: 6 Issue: 4 |
Interuniversity Board (UAK) Equivalency: Article published in Ulakbim TR Index journal [10 POINTS], and Article published in other (excuding 1a, b, c) international indexed journal (1d) [5 POINTS].
The Directories (indexes) and Platforms we are included in are at the bottom of the page.
Note: Our journal is not WOS indexed and therefore is not classified as Q.
You can download Council of Higher Education (CoHG) [Yüksek Öğretim Kurumu (YÖK)] Criteria) decisions about predatory/questionable journals and the author's clarification text and journal charge policy from your browser. https://dergipark.org.tr/tr/journal/2316/file/4905/show
The indexes of the journal are ULAKBİM TR Dizin, Index Copernicus, ICI World of Journals, DOAJ, Directory of Research Journals Indexing (DRJI), General Impact Factor, ASOS Index, WorldCat (OCLC), MIAR, EuroPub, OpenAIRE, Türkiye Citation Index, Türk Medline Index, InfoBase Index, Scilit, etc.
|
|
|
| |
|
|
|
|
The platforms of the journal are Google Scholar, CrossRef (DOI), ResearchBib, Open Access, COPE, ICMJE, NCBI, ORCID, Creative Commons, etc.
|
|
|
|
|
|
Our Journal using the DergiPark system indexed are;
Ulakbim TR Dizin, Index Copernicus, ICI World of Journals, Directory of Research Journals Indexing (DRJI), General Impact Factor, ASOS Index, OpenAIRE, MIAR, EuroPub, WorldCat (OCLC), DOAJ, Türkiye Citation Index, Türk Medline Index, InfoBase Index
Our Journal using the DergiPark system platforms are;
Journal articles are evaluated as "Double-Blind Peer Review".
Our journal has adopted the Open Access Policy and articles in JHSM are Open Access and fully comply with Open Access instructions. All articles in the system can be accessed and read without a journal user. https//dergipark.org.tr/tr/pub/jhsm/page/9535
Journal charge policy https://dergipark.org.tr/tr/pub/jhsm/page/10912
Editor List for 2022
Assoc. Prof. Alpaslan TANOĞLU (MD)
Prof. Aydın ÇİFCİ (MD)
Prof. İbrahim Celalaettin HAZNEDAROĞLU (MD)
Prof. Murat KEKİLLİ (MD)
Prof. Yavuz BEYAZIT (MD)
Prof. Ekrem ÜNAL (MD)
Prof. Ahmet EKEN (MD)
Assoc. Prof. Ercan YUVANÇ (MD)
Assoc. Prof. Bekir UÇAN (MD)
Assoc. Prof. Mehmet Sinan DAL (MD)
Our journal has been indexed in DOAJ as of May 18, 2020.
Our journal has been indexed in TR-Dizin as of March 12, 2021.
Articles published in the Journal of Health Sciences and Medicine have open access and are licensed under the Creative Commons CC BY-NC-ND 4.0 International License.